Aqupla
(Nedaplatin)ApprovedSmall molecule
Jiangsu Simcere Pharmaceutical Co., Ltd.Nedaplatin is a chemotherapy drug used to treat various cancers, particularly ovarian cancer and lung cancer, by stopping cancer cells from growing and dividing.[2] Aqupla is currently approved and in use across 13 indications[4].[1]
Aqupla is one of 327 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Approved.
13
Indications
28
Total Trials
9
Active Trials
326
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Approved
Tecentriq
RochePreclinical
Spravato
WWim Janssens
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Neoadjuvant Therapy
SSun Yat-sen University
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nasopharyngeal Carcinoma6 trials
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
Recruiting·—·Phase 3·NCT04437329·352 enrolled
Show 3 more trials
Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma
Unknown status·—·Phase 2·NCT01265147·20 enrolled
Nedaplatin in Treatment for Nasopharyngeal Carcinoma
Completed·—·Phase 2·NCT04834206·32 enrolled
Esophageal Squamous Cell Carcinoma4 trials
Esophageal Carcinoma3 trials
Esophageal Cancer1 trial
Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer
Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT03649945·186 enrolled
13 more indications
Lymphoma1 trial
Esophageal Squamous Carcinoma1 trial
Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma
Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT07019181·26 enrolled
Cervical Cancer1 trial
Pelvic External Combined With 252-Cf Neutron Intracavitary Radiotherapy With or Without Platinum in Treating Advanced Cervical Cancer
Unknown status·—·Phase 2·NCT02835404·200 enrolled
Breast Cancer1 trial
Capecitabine1 trial
Squamous Cell Carcinoma1 trial
Head and Neck Squamous Cell Carcinoma1 trial
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Unknown status·—·Phase 2·NCT06170697·46 enrolled
Lung Cancer1 trial
Phase II Clinical Trial1 trial
Neoadjuvant Treatment1 trial
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Recruiting·—·Phase 3·NCT06102395·272 enrolled
Salivary Gland Carcinoma1 trial
Esophageal Squamous Cell Cancer1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Aqupla drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Nedaplatin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details